Edwards Lifesciences Financial Ratios

Edwards Lifesciences Corporation -- USA Stock  

USD 117.1  1.08  0.91%

Use fundamental data analysis to check all available reported financial drivers of Edwards Lifesciences to find out if markets are presently mispricing the company. We found thirty-five available fundamental indicators for Edwards Lifesciences Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Edwards Lifesciences fundamentals including its EBITDA, Earnings Per Share, Z Score, as well as the relationship between Debt to Equity and Total Asset . Given that Edwards Lifesciences has Price to Earning of 34.46 times, we urge you verify Edwards Lifesciences Corporation prevailing market performance to make sure the company can sustain itself down the road.Use Edwards Lifesciences to protect against small markets fluctuations. The stock experiences moderate downward daily trend and can be a good diversifier. Check odds of Edwards Lifesciences to be traded at $114.76 in 30 days

Edwards Lifesciences Valuation Over Time

Enterprise Value

Edwards Lifesciences Company Summary

Edwards Lifesciences competes with Express Scripts, AmerisourceBergen, Baxter International, and BARD C. It offers transcatheter heart valve therapy solutions comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. Edwards Lifesciences Corp also offer surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system and tissue heart valves and repair products, which are used to replace or repair a patients diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue and offer heart valve repair therapies, including annuloplasty rings and systems. Further, Edwards Lifesciences Corp offers critical care products, such as hemodynamic monitoring systems to measure a patients heart function in surgical and intensive care settings pulmonary artery catheters and continuous venous oximetry catheter for measuring central venous oxygen saturation. Additionally, its critical care solutions include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection and peripheral vascular solutions used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. Edwards Lifesciences Corp distributes its solutions through direct sales force and independent distributors. Edwards Lifesciences Corporationration was founded in 1999 and is headquartered in Irvine, California.

Edwards Lifesciences Working Capital vs Operating Margin

Edwards Lifesciences Corporation is rated # 4 in working capital category among related companies. It is rated # 2 in operating margin category among related companies . The ratio of Working Capital to Operating Margin for Edwards Lifesciences Corporation is about  52,442,442 

Edwards Lifesciences Systematic Risk

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Edwards Lifesciences correlated with the market. If Beta is less then 0 Edwards Lifesciences generally moves in the opposite direction as compared to the market. If Edwards Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Edwards Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Edwards Lifesciences is generally in the same direction as the market. If Beta > 1 Edwards Lifesciences moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
< 1% 

Chance of Financial Distress

Edwards Lifesciences Corporation has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
Details

Growth

Edwards Lifesciences Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth

Compare

Compare Edwards Lifesciences To Peers
Michael Mussallem Chairman and CEO, Ph.D
Catherine Szyman Corporate Vice President Critical Care, MBA
More Executives

Opportunity Range

December 12, 2017 Opportunity Range